https://medicine.ouhsc.edu/Academic-Departments Parent Page: Academic Departments id: 21934 Active Page: Gynecologic Oncologyid:23718

Gynecologic Oncology Faculty

Doris M Benbrook

Doris M Benbrook, PhD

Assistant Professor

405/271-5523

doris-benbrook@ouhsc.edu


Education:

  • Loyola University Medical Center, Maywood, IL, PhD, 1985, Biochemistry
  • North Central College, Naperville, IL BA 1981, Biology/Chemistry
  • La Jolla Cancer Research Foundation, La Jolla, CA Postdoc, 1988, Nuclear Receptors in Cancer
  • Imperial Cancer Research Fund, London, England, Postdoc, 1991, CREB and JUN Transcription Factors


Select Publications:

Ramraj SK, Elayapillai SP, Pelikan RC, Zhao YD, Isingizwe ZR, Kennedy AL, Lightfoot SA, Benbrook DM. Novel ovarian cancer maintenance therapy targeted at mortalin and mutant p53. Int J Cancer. 2019 Dec 17. PMID: 31845320.

View in: PubMed 

Gnanasekaran KK, Pouland T, Bunce RA, Darrell Berlin K, Abuskhuna S, Bhandari D, Mashayekhi M, Zhou DH, Benbrook DM. Tetrahydroquinoline units in flexible heteroarotinoids (Flex-Hets) convey anti-cancer properties in A2780 ovarian cancer cells. Bioorg Med Chem. 2020 Jan 01; 28(1):115244. PMID: 31831296.

View in: PubMed

Csiszar A, Balasubramanian P, Tarantini S, Yabluchanskiy A, Zhang XA, Springo Z, Benbrook D, Sonntag WE, Ungvari Z. Chemically induced carcinogenesis in rodent models of aging: assessing organismal resilience to genotoxic stressors in geroscience research. Geroscience. 2019 04; 41(2):209-227. PMID: 31037472.

View in: PubMed

Nammalwar B, Bunce RA, Berlin KD, Benbrook DM, Toal C. Synthesis and biological evaluation of SHetA2 (NSC-721689) analogs against the ovarian cancer cell line A2780. Eur J Med Chem. 2019 May 15; 170:16-27. PMID: 30878829.

View in: PubMed 

Watts FM, Pouland T, Bunce RA, Berlin KD, Benbrook DM, Mashayekhi M, Bhandari D, Zhou D. Activity of oxygen-versus sulfur-containing analogs of the Flex-Het anticancer agent SHetA2. Eur J Med Chem. 2018 Oct 05; 158:720-732. PMID: 30245396.

View in: PubMed

Mahjabeen S, Hatipoglu MK, Benbrook DM, Garcia-Contreras L. Pharmacokinetics and Pharmacodynamics of Escalating Doses of SHetA2 After Vaginal Administration to Mice. J Pharm Sci. 2018 12; 107(12):3179-3186. PMID: 30196041.

View in: PubMed

Mahjabeen S, Hatipoglu MK, Benbrook DM, Kosanke SD, Garcia-Contreras D, Garcia-Contreras L. Influence of the estrus cycle of the mouse on the disposition of SHetA2 after vaginal administration. Eur J Pharm Biopharm. 2018 Sep; 130:272-280. PMID: 30064701.

View in: PubMed

Carlson BW, Craft MA, Carlson JR, Razaq W, Deardeuff KK, Benbrook DM. Accelerated vascular aging and persistent cognitive impairment in older female breast cancer survivors. Geroscience. 2018 06; 40(3):325-336. PMID: 29804200.

View in: PubMed

Sharma A, Benbrook DM, Woo S. Pharmacokinetics and interspecies scaling of a novel, orally-bioavailable anti-cancer drug, SHetA2. PLoS One. 2018; 13(4):e0194046. PMID: 29634717.

View in: PubMed

Ramraj SK, Smith KM, Janakiram NB, Toal C, Raman A, Benbrook DM. Correlation of clinical data with fallopian tube specimen immune cells and tissue culture capacity. Tissue Cell. 2018 Jun; 52:57-64. PMID: 29857829.

View in: PubMed